Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J R Coll Physicians Lond ; 34(5): 448-51, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11077656

RESUMO

UNLABELLED: We have investigated bile acid malabsorption (BAM), and its response to treatment, in patients seen in this district general hospital with chronic continuous or recurrent diarrhoea. METHODS: Seven-day retention of 75-SeHCAT was measured (normal: > 10%). TREATMENT: Patients were initially given conventional therapy (prednisolone +/- ASA drugs in Crohn's disease, and antidiarrhoeals in the others). If this therapy failed, bile acid sequestrants (BAS) were prescribed. The definition of successful response was based on the patient's perception of sustained improvement. PATIENTS: The 304 patients were categorised as follows: Group 1: Crohn's disease patients with ileal resection, in clinical remission (n = 37). Group 2: Crohn's disease, unoperated and in clinical remission (n = 44). Group 3: vagotomy and pyloroplasty, with/without cholecystectomy (n = 26). Group 4: diarrhoea predominant 'irritable bowel syndrome' (IBS) (n = 197). RESULTS: BAM was found in 97% (36/37), 54% (24/44) and 58% (15/26) of patients in groups 1, 2 and 3 respectively. One third (65/197) of patients with IBS had BAM. The outcome of treatment was available in 96 patients with BAM: of the patients with ileal resection 32% responded to antidiarrhoeals, 60% to BAS. Of the unoperated Crohn's patients 55% responded to disease-specific therapy, 40% to BAS. Of the gastric surgery patients 18% responded to conventional treatment, 64% to BAS. Of the IBS patients 15% of responded to conventional therapy, 70% to BAS. CONCLUSIONS: This observational study indicates that BAM is common in patients with chronic diarrhoea, and is frequently found in IBS. The results of open treatment suggest that, where antidiarrhoeal drugs fail in such patients, BAS are often effective.


Assuntos
Ácidos e Sais Biliares/metabolismo , Doenças Funcionais do Colo/complicações , Doença de Crohn/complicações , Doença de Crohn/metabolismo , Diarreia/etiologia , Antidiarreicos/uso terapêutico , Doença Crônica , Doenças Funcionais do Colo/metabolismo , Doença de Crohn/fisiopatologia , Doença de Crohn/cirurgia , Diarreia/tratamento farmacológico , Humanos , Absorção Intestinal , Ácido Taurocólico/análogos & derivados , Ácido Taurocólico/isolamento & purificação
6.
Proc Natl Acad Sci U S A ; 68(1): 63-7, 1971 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-4322265

RESUMO

Determination of the amino acid sequence of bovine parathyroid hormone has led to the synthesis of a tetratriacontapeptide corresponding to the amino-terminal 1-34 residues of the native molecule. The specific biological effects of this synthetic peptide on bone and kidney are qualitatively identical to those of the native hormone in classical bioassays in vivo and in several systems in vitro. Potency of the synthetic peptide equals or exceeds that of a biologically active fragment of comparable size isolated from the native hormone; the synthetic and natural peptides show complete immunological cross-reactivity. Thus, essential requirements for the physiological actions of the peptide on both skeletal and renal tissue are contained within the 34 amino-terminal amino acids. The potency of the synthetic peptide, relative to that of the native (84-amino acid) polypeptide, is greater in vitro than in vivo; this suggests that the carboxyl terminal two-thirds of the native hormone may protect the circulating polypeptide from rapid metabolic degradation.


Assuntos
Sequência de Aminoácidos , Hormônio Paratireóideo/síntese química , Peptídeos/síntese química , Adenilil Ciclases/metabolismo , Animais , Bioensaio , Cálcio/sangue , AMP Cíclico/urina , Cães , Ativação Enzimática , Rim/enzimologia , Hormônio Paratireóideo/análise , Hormônio Paratireóideo/farmacologia , Peptídeos/farmacologia , Fosfatos/urina , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA